Harrow, Inc.

HROW Healthcare Drug Manufacturers Specialty & Generic

Harrow, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $272.3 million, up 36.4% from fiscal 2024. In the quarter to June 2026, revenue grew 10.9%, EPS fell 428.6%, free cash flow fell 838.8% and total debt rose 659.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

27.28 1.47 −5.11%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
134×
Dividend yield
—
F-score
6/9
Altman Z
3.84
Beneish M
−3.04
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
7.16 6.61 4.89 5.76
P/FCF ratio
0.00 42.12 0.00 0.00
P/Operating CF
107.89 214.16 (145.99) (162.61)
P/B ratio
38.35 34.58 46.30 106.86
EV/Sales
7.85 7.25 5.64 6.53
EV/EBITDA
37.55 36.42 34.86 84.00
EV/FCF
(95.18) 46.20 (389.33) (137.49)
Current Ratio
2.72 2.20 2.48 2.24
Net Debt/EBITDA
8.12 8.14 (12.45) (47.14)
Debt/Equity
5.21 4.67 10.30 19.70
Earnings Yield
(0.29%) (0.31%) (1.11%) (2.33%)
Free Cash Flow Yield
(1.15%) 2.37% (0.30%) (0.82%)
Free Cash Flow per Share
0.44 0.22 (0.73) (0.28)
Book value per Share
1.26 1.42 0.76 0.40
Free Cash Flow
16.36 8.04 (27.19) (10.29)
EV/EBIT
70.52 64.74 76.99 0.00
Other line items

Show all line items

Columns are period end dates